Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (41-50 of 177) with videos related to

Pageof 18
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|June 1, 2011
Etiology and pathogenesis of Parkinson's diseaseAnthony H Schapira, Peter Jenner
European Journal of Neurology|July 25, 2023
The 20th anniversary of the first clinical use of Stalevo<sup>®</sup>Peter Jenner, Werner Poewe, Heinz Reichmann
Experimental Neurology|September 15, 2014
Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicityLauren Broom, Peter Jenner, Sarah Rose
Journal of Parkinson'S Disease|April 1, 2016
Parkinson's Inside OutJon Stamford, Dieter Scheller, Peter Jenner
Parkinsonism & Related Disorders|December 22, 2020
Can adenosine A<sub>2A</sub> receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?Peter Jenner, Akihisa Mori, Tomoyuki Kanda
The European Journal of Neuroscience|May 5, 2005
Increased osteopontin expression following intranigral lipopolysaccharide injection in the ratJoanna Iczkiewicz, Sarah Rose, Peter Jenner
Brain Research. Molecular Brain Research|November 19, 2004
Osteopontin (Eta-1) is present in the rat basal gangliaJoanna Iczkiewicz, Sarah Rose, Peter Jenner
Experimental Neurology|July 24, 2007
Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell lossJoanna Iczkiewicz, Sarah Rose, Peter Jenner
International Review of Neurobiology|September 23, 2023
How and why the adenosine A<sub>2A</sub> receptor became a target for Parkinson's disease therapyPeter Jenner, Tomoyuki Kanda, Akihisa Mori
Handbook of Experimental Pharmacology|July 30, 2009
Adenosine A2A receptors and Parkinson's diseaseMicaela Morelli, Anna R Carta, Peter Jenner
Pageof 18

Showing results (41-50 of 177) with videos related to

Sort By:
Pageof 18
Movement Disorders : Official Journal of the Movement Disorder Society|June 1, 2011
Etiology and pathogenesis of Parkinson's diseaseAnthony H Schapira, Peter Jenner
European Journal of Neurology|July 25, 2023
The 20th anniversary of the first clinical use of Stalevo<sup>®</sup>Peter Jenner, Werner Poewe, Heinz Reichmann
Experimental Neurology|September 15, 2014
Increased neurotrophic factor levels in ventral mesencephalic cultures do not explain the protective effect of osteopontin and the synthetic 15-mer RGD domain against MPP+ toxicityLauren Broom, Peter Jenner, Sarah Rose
Journal of Parkinson'S Disease|April 1, 2016
Parkinson's Inside OutJon Stamford, Dieter Scheller, Peter Jenner
Parkinsonism & Related Disorders|December 22, 2020
Can adenosine A<sub>2A</sub> receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?Peter Jenner, Akihisa Mori, Tomoyuki Kanda
The European Journal of Neuroscience|May 5, 2005
Increased osteopontin expression following intranigral lipopolysaccharide injection in the ratJoanna Iczkiewicz, Sarah Rose, Peter Jenner
Brain Research. Molecular Brain Research|November 19, 2004
Osteopontin (Eta-1) is present in the rat basal gangliaJoanna Iczkiewicz, Sarah Rose, Peter Jenner
Experimental Neurology|July 24, 2007
Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell lossJoanna Iczkiewicz, Sarah Rose, Peter Jenner
International Review of Neurobiology|September 23, 2023
How and why the adenosine A<sub>2A</sub> receptor became a target for Parkinson's disease therapyPeter Jenner, Tomoyuki Kanda, Akihisa Mori
Handbook of Experimental Pharmacology|July 30, 2009
Adenosine A2A receptors and Parkinson's diseaseMicaela Morelli, Anna R Carta, Peter Jenner
Pageof 18